Lilly and OliX Partner in MASH; Hims & Hers Super Bowl Ad Controversy; Novartis Initiates Pelacarsen/Inclisiran Trial in Lp(a)
Three cardiometabolic-related news items have been observed: OliX Pharmaceuticals announced a partnership with Lilly in MASH (view press release); Hims & Hers received congressional scrutiny over the company’s Super Bowl ad (view article); and Novartis initiated a Ph3 pelacarsen/inclisiran Lp(a) trial (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.